The global breast biopsy market size was valued at USD 2.83 billion in 2025 and is projected to grow from USD 3.14 billion in 2026 to USD 7.12 billion by 2034, registering a CAGR of 10.8% during the forecast period from 2026 to 2034. North America dominated the breast biopsy market with a market share of 38.6% in 2025.
A breast biopsy is a diagnostic procedure used to remove a small sample of breast tissue or cells for laboratory examination to determine whether an abnormal area is benign or cancerous. It may be performed using fine-needle aspiration, core needle biopsy, vacuum-assisted biopsy, or surgical methods. Breast biopsies play an important role in confirming breast cancer diagnoses and guiding appropriate treatment decisions.
Download a Free Sample To learn more about this report,
Growing Adoption of Advanced Image-Guided Breast Biopsy Technologies
The breast biopsy market is advancing as hospitals and diagnostic centers adopt image-guided technologies that improve lesion targeting and tissue collection. Tomosynthesis, contrast-enhanced mammography, MRI, and ultrasound guidance help clinicians locate suspicious breast abnormalities more accurately while supporting minimally invasive procedures. Modern systems also combine automation and imaging to shorten workflows and improve patient comfort. This technological shift is supporting the breast biopsy market size as healthcare providers focus on earlier and more accurate breast cancer diagnosis.
Increasing Use of Contrast-Enhanced Imaging for Precise Biopsy Targeting
Another important trend is the integration of contrast-enhanced mammography with biopsy guidance. This approach enables clinicians to directly target suspicious lesions identified through contrast imaging, helping streamline diagnostic workflows. These developments are supporting breast biopsy market growth as breast centers seek efficient alternatives for evaluating abnormalities that may be difficult to identify using conventional imaging.
Rising Breast Cancer Screening and Need for Accurate Diagnosis
The breast biopsy market is experiencing steady growth as expanding breast cancer screening increases the identification of suspicious breast lesions that require further diagnostic evaluation. Core needle, vacuum-assisted, and image-guided biopsy procedures allow physicians to collect tissue for pathological examination and determine whether abnormalities are benign or malignant. Greater awareness of early breast cancer detection and improvements in mammography, ultrasound, and MRI are supporting more precise lesion identification. These factors continue to strengthen breast biopsy market demand across hospitals, breast imaging centers, and diagnostic facilities.
Procedure-Related Discomfort and Risk of Complications
The breast biopsy market faces restraints because biopsy procedures are invasive and can cause temporary pain, bruising, bleeding, swelling, or infection. Patient anxiety surrounding the procedure and possible cancer diagnosis can also influence willingness to undergo timely testing. Image-guided procedures require specialized equipment and trained healthcare professionals, which can limit availability in healthcare systems with fewer diagnostic resources. Costs associated with imaging, pathology, and follow-up care create additional barriers in some regions. These factors continue to influence the overall breast biopsy market analysis, particularly where access to specialized breast diagnostic services remains limited.
Expansion of Advanced Image-Guided and Vacuum-Assisted Biopsy Technologies
The breast biopsy market presents significant opportunities as healthcare providers adopt more precise image-guided technologies for sampling small or difficult-to-access breast lesions. Stereotactic mammography, ultrasound, MRI guidance, and vacuum-assisted systems can improve targeting while allowing clinicians to obtain sufficient tissue for pathological and molecular testing. Integration with advanced breast imaging and digital workflow technologies could further improve procedural efficiency and diagnostic confidence. These developments continue to support positive breast biopsy market trends and create opportunities for manufacturers offering minimally invasive diagnostic solutions.
Ensuring Accurate Tissue Sampling and Diagnostic Interpretation
The breast biopsy market continues to face challenges in obtaining representative tissue samples from heterogeneous, very small, or difficult-to-reach lesions. Inadequate sampling can result in inconclusive findings and may require repeat biopsy or surgical evaluation. Radiologists, pathologists, and surgeons must also maintain close coordination to ensure that imaging findings correspond with pathology results. Increasing use of molecular testing creates additional requirements for obtaining sufficient high-quality tissue. Addressing these issues will remain essential for strengthening the future breast biopsy market report and improving diagnostic accuracy.
Biopsy Needles Segment Dominated the Market with 29.4% Share in 2025
The biopsy needles segment dominated the global breast biopsy market with a 29.4% market share in 2025, valued at USD 0.83 billion. The segment's dominance is driven by the widespread use of biopsy needles for obtaining breast tissue samples, their suitability for minimally invasive procedures, and their extensive application in breast cancer diagnosis. Growing demand for early and accurate detection continues to support adoption.
The biopsy forceps, guidance systems, needle-based biopsy guns, localization wires, and other guidance techniques continue to support breast biopsy procedures by improving tissue collection, lesion localization, and procedural accuracy. Technological advancements in biopsy devices are further supporting their adoption.
Request Customizationto receive a tailored report.
The liquid breast biopsy segment is Projected to Register the Fastest Growth at a CAGR of 10.36%
The liquid breast biopsy segment is projected to register the fastest growth at a CAGR of 10.36% during the forecast period. Growing interest in minimally invasive cancer diagnostics, advances in circulating biomarker analysis, and increasing research into blood-based approaches for cancer detection and monitoring are supporting segment growth.
The fine-needle aspiration biopsy, core needle biopsy, vacuum-assisted breast biopsy, excisional and incisional breast biopsy, and open surgical breast biopsy segments continue to play important roles in breast cancer diagnosis. Their use varies according to lesion characteristics, clinical requirements, and the amount of tissue required for analysis.
The image-guided biopsy segment dominated the Market with 88.3% Share in 2025
The image-guided biopsy segment dominated the global breast biopsy market with an 88.3% market share in 2025, valued at USD 2.50 billion. The segment's leadership is driven by the widespread use of imaging technologies to accurately locate suspicious breast abnormalities and guide tissue sampling. Greater procedural precision and the ability to target difficult-to-detect lesions continue to support its strong adoption.
The liquid biopsy segment continues to gain attention as a minimally invasive approach for identifying and monitoring cancer-related biomarkers. Ongoing developments in molecular diagnostics and precision oncology are expanding the potential role of liquid biopsy in breast cancer management.
The recurrence monitoring segment is Projected to Register the Fastest Growth at a CAGR of 8.49%
The recurrence monitoring segment is projected to register the fastest growth at a CAGR of 8.49% during the forecast period. Increasing emphasis on post-treatment surveillance, early identification of cancer recurrence, and personalized follow-up strategies is driving demand for advanced biopsy and diagnostic approaches for monitoring breast cancer patients.
The early cancer screening, therapy selection, and treatment monitoring segments continue to generate strong demand as breast biopsy plays an important role throughout cancer diagnosis and treatment planning. Growing emphasis on early detection and personalized treatment decisions is supporting these applications.
Hospitals and Surgical Centers Segment Dominated the Market with 51.6% Share in 2025
The hospitals and surgical centers segment dominated the global breast biopsy market with a 51.6% market share in 2025, valued at USD 1.46 billion. The segment's dominance is driven by access to advanced diagnostic equipment, skilled medical professionals, surgical capabilities, and comprehensive breast cancer care services. Their ability to manage complex diagnostic procedures further supports their leading position.
The breast care centers and imaging and diagnostic centers continue to witness steady demand due to their specialized diagnostic capabilities and focus on breast health services. Increasing availability of dedicated breast imaging and biopsy facilities is supporting their role in early diagnosis and patient management.
Speak to an Analystto discuss market opportunities.
North America's breast biopsy market accounted for 38.6% of the global market, reaching USD 1.09 billion in 2025, and is projected to grow at a CAGR of 6.91% during the forecast period. Market growth is driven by widespread breast cancer screening, increasing awareness of early diagnosis, strong healthcare infrastructure, and growing adoption of minimally invasive image-guided biopsy procedures and advanced diagnostic technologies.
The United States represents the largest market in North America. Extensive breast cancer screening programs, strong availability of advanced imaging and biopsy technologies, increasing use of core needle and vacuum-assisted biopsy procedures, and established diagnostic infrastructure continue to support market growth.
Increasing breast cancer screening, growing awareness of early disease detection, expanding availability of image-guided biopsy procedures, and improvements in diagnostic healthcare infrastructure continue to support steady market development.
Unlock Regional Insightsto access country-level data, & regional trends.
The European breast biopsy market accounted for 28.4% of the global market, reaching USD 0.80 billion in 2025, and is expected to register a CAGR of 6.74% during the forecast period. Established breast cancer screening programs, increasing adoption of minimally invasive biopsy procedures, growing use of advanced imaging technologies, and rising emphasis on early cancer diagnosis continue to support regional market expansion.
Germany represents a major European market. Established cancer screening infrastructure, increasing utilization of image-guided breast biopsy, availability of advanced diagnostic technologies, and growing emphasis on accurate and early breast cancer diagnosis continue to support market growth.
Organized breast screening programs, increasing demand for minimally invasive diagnostic procedures, growing adoption of advanced breast imaging technologies, and continued focus on early cancer detection support market development.
The Asia Pacific breast biopsy market accounted for 22.7% of the global market, reaching USD 0.64 billion in 2025, and is projected to register a CAGR of 9.18% during the forecast period. The region represents the fastest-growing market, supported by increasing breast cancer awareness, improving access to diagnostic services, expanding healthcare infrastructure, rising screening participation, and growing adoption of advanced biopsy and imaging technologies.
China represents a major market within the Asia Pacific. Expanding cancer screening initiatives, increasing awareness of breast cancer, improving hospital diagnostic capabilities, and growing adoption of minimally invasive biopsy technologies continue to drive market expansion.
Increasing awareness of breast cancer, expansion of specialized diagnostic centers, improving access to mammography and image-guided procedures, and rising investment in cancer diagnosis and treatment infrastructure continue to strengthen market growth.
Latin America's breast biopsy market accounted for 6.1% of the global market, reaching USD 0.17 billion in 2025, and is expected to grow at a CAGR of 7.36% during the forecast period. Improving access to breast cancer screening, increasing awareness of early diagnosis, expanding private healthcare infrastructure, and rising availability of modern biopsy technologies continue to support regional market development.
Brazil represents a major regional market. Increasing breast cancer screening, expanding diagnostic infrastructure, growing availability of specialized cancer centers, and rising adoption of image-guided biopsy procedures continue to create market opportunities.
The Middle East & Africa breast biopsy market accounted for 4.2% of the global market, reaching USD 0.12 billion in 2025, and is anticipated to grow at a CAGR of 6.89% during the forecast period. Increasing awareness of breast cancer, improving diagnostic capabilities, expanding healthcare infrastructure, and growing investments in specialized oncology and women's health services continue to support regional market expansion.
Increasing investment in cancer care infrastructure, growing breast cancer awareness and screening initiatives, expanding availability of advanced imaging systems, and improving access to specialized diagnostic services continue to support market development.
Growing awareness of early breast cancer detection, improving access to diagnostic services, expanding oncology facilities, and increasing availability of minimally invasive biopsy procedures continue to support steady market growth.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Her work focuses on assessing treatment landscapes, outsourcing models, technology adoption, market access dynamics, regulatory developments, and competitive positioning across healthcare and life sciences industries. Debashree has consistently supported organizations in understanding market gaps, evaluating revenue potential, developing market entry strategies, and shaping expansion plans across complex and fast evolving healthcare markets.
With a strong analytical foundation and structured research approach, she excels at synthesizing large datasets, stakeholder inputs, and market signals into actionable insights that guide strategic decision making. Her healthcare expertise enables her to connect clinical, commercial, and operational developments with business opportunities, helping stakeholders anticipate shifts and capitalize on emerging growth areas. Debashree’s consulting oriented mindset and deep healthcare industry understanding make her a trusted advisor to businesses navigating dynamic and rapidly evolving healthcare markets.
Assisted Walking Devices Market Size, Share, Growth, 2034
Spirometer Market Size, Share, Growth, Analysis, Report, 2034
Vessel Sealing Devices Market Size, Share, Growth, Analysis, 2034
ECG Patch and Holter Monitor Market Size, Share, Growth, 2034
Tampon Market Size, Share, Growth, Opportunities, Analysis, 2034
Artificial Cornea and Corneal Implant Market Size, Share, 2034
We are featured on:
sales@straitsresearch.com